Dr. Guarino on IMMU-132 in Advanced Metastatic Lung Cancer

Michael J. Guarino, MD
Published: Friday, Jun 26, 2015



Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-ΤROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.

IMMU-132 was designed to target TROP-2, a protein expressed in most cancer cells, Guarino says. IMMU-132 internalizes into these cells with SN-38, a component of irinotecan. This is a novel way to deliver a higher dose of this agent to TROP-2, Guarino explains. Therefore, toxicities on normal cells are less than standard cytotoxic chemotherapy agents.

Though results of this study are preliminary, it appears IMMU-132 demonstrates activity in these patients, he adds.



Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-ΤROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.

IMMU-132 was designed to target TROP-2, a protein expressed in most cancer cells, Guarino says. IMMU-132 internalizes into these cells with SN-38, a component of irinotecan. This is a novel way to deliver a higher dose of this agent to TROP-2, Guarino explains. Therefore, toxicities on normal cells are less than standard cytotoxic chemotherapy agents.

Though results of this study are preliminary, it appears IMMU-132 demonstrates activity in these patients, he adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x